Details for Patent: 10,463,673

Which drugs does patent 10,463,673 protect, and when does it expire?

Patent 10,463,673 protects ANJESO and is included in one NDA.

This patent has eighteen patent family members in nine countries.

Summary for Patent: 10,463,673

Title:	Nanoparticulate meloxicam formulations
Abstract:	The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Inventor(s):	Cooper; Eugene R. (Berwyn, PA), Ryde; Tuula (Malvern, PA), Pruitt; John (Suwanee, GA), Kline; Laura (Harleysville, PA)
Assignee:	Recro Pharma, Inc. (Malvern, PA)
Application Number:	15/950,367
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,463,673
Patent Claim Types: see list of patent claims	Use; Compound; Dosage form;

Drugs Protected by US Patent 10,463,673

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No			Y			MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION

International Family Members for US Patent 10,463,673

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	431131
Canada	2517679
Germany	602004021107
Denmark	3090731
Denmark	3434261